Abstract:3515 Background: Neoadjuvant radiochemotherapy is the standard treatment for locally advanced rectal cancer. However, radiation therapy can lead to bowel, urinary and sexual dysfunction. The study aims to clarify whether locally advanced rectal cancer with a distance of 6 to 12 cm from the anus with negative circumferential margins (CRM) predicted by MRI can be exempted from preoperative radiotherapy. Methods: PSSR (NCT02121405), a multicentre, randomized, open-label, non-inferiority, phase 3 trial, was done across 10 hospitals in China. Patients aged from 18 to 75 years with locally advanced rectal cancer (including all cT3/4 and/or Nany) with negative MRI-predicted CRM and tumor distance of 6 to 12 cm from anus were randomly assigned (1:1), by central randomization, to intervention group (surgery directly, in which positive CRM was supplemented with chemoradiotherapy, negative CRM received adjuvant chemotherapy according to surgical pathologic staging), or control group (neoadjuvant chemoradiotherapy then underwent surgery and adjuvant chemotherapy). The primary endpoint is the rate of 3-year disease-free survival (DFS). A sample size of 350 was set according to the original non-inferiority margin of 15% for the difference of rates for 3-year DFS, which was changed to 5% under the Data Safety Monitoring Board (DSMB) suggestion after an interim analysis. The efficacy analysis followed the per-protocol (PP) principle. Results: From December 2015 to February 2021, 299 patients were recruited. DSMB stopped this trial due to the difference of 3-year DFS’s rate between two groups more than 5% at the interim analysis in July 2021. A total of 275 were included for the final analysis. Based on the PP dataset, 238 patients followed the original protocol (135 patients in the intervention group and 103 patients in the control group). Patients who had positive CRM were 2(1.5%) and 1(1.0%) in two groups, respectively ( P= 1.00). After a median follow-up of 34.6 (IQR: 18.2-45.7) months, a total of 42 patients had positive events (30 patients in the intervention group and 12 patients in the control group). There were 5 (3.7%) patients with local recurrence in the intervention group ( P= 0.062). Patients with pathological complete response (pCR) and near pCR were 19 (18.4%) and 21 (20.4%) in the control group. The rate of 3-year DFS was 81.1% (77.3%-84.9%) (HR = 2.02, 95%CI: 1.01-4.06, P= 0.048) in the intervention group and 86.6% (82.7%-90.5%) in the control group, with difference of 5.4% (5.3%-5.6%), which did not meet the criteria for non-inferiority. Conclusions: In terms of DFS, initial surgery was inferior to conventional preoperative radiochemotherapy for locally advanced middle rectal cancer with MRI negative circumferential margin. Clinical trial information: NCT02121405.

Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multi-center, Randomized, Open-label, Prospective Trial

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Pre-operative radiochemotherapy of locally advanced rectal cancer.

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

A Clinical Study to Evaluate the Toxicities of Adjuvant Chemoradiotherapy in Early Stage after Low-Anterior Resection for Locally Advanced Rectal Cancer

Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant radiotherapy for stages II-III rectal cancer: a Meta-analysis

Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer.

Primary surgery followed by selective radiochemotherapy versus conventional preoperative radiochemotherapy for patients with locally advanced rectal cancer with MRI-negative circumferential margin (PSSR): A multicenter, randomized, open-label, noninferiority, phase 3 trial.

Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: A phase II PRECAM experimental study

Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy with Concurrent Capecitabine for Locally Advanced Rectal Cancer

Phase Ii Trial Of Neoadjuvant Chemoradiation With Concomitant Boost Followed By A Coycle Of Xelox In Locally Advanced Rectal Cancer

A single-institution experience of acute toxicities in patients treated with short course hypofractionated radiotherapy in locally advanced rectal cancer.

The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review

Retrospective analysis of efficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer

Endorectal Epinephrine Suspension May Protect Against Radiation Proctitis During Radiation Therapy for Pelvic Tumor

Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)

Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E)